SG11201502301YA - Azaquinazoline inhibitors of atypical protein kinase c - Google Patents
Azaquinazoline inhibitors of atypical protein kinase cInfo
- Publication number
- SG11201502301YA SG11201502301YA SG11201502301YA SG11201502301YA SG11201502301YA SG 11201502301Y A SG11201502301Y A SG 11201502301YA SG 11201502301Y A SG11201502301Y A SG 11201502301YA SG 11201502301Y A SG11201502301Y A SG 11201502301YA SG 11201502301Y A SG11201502301Y A SG 11201502301YA
- Authority
- SG
- Singapore
- Prior art keywords
- azaquinazoline
- inhibitors
- protein kinase
- atypical protein
- atypical
- Prior art date
Links
- 101710082924 Atypical protein kinase C Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
- C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261707340P | 2012-09-28 | 2012-09-28 | |
| US201361781364P | 2013-03-14 | 2013-03-14 | |
| PCT/US2013/062085 WO2014052699A1 (en) | 2012-09-28 | 2013-09-27 | Azaquinazoline inhibitors of atypical protein kinase c |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201502301YA true SG11201502301YA (en) | 2015-04-29 |
Family
ID=49326872
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201502301YA SG11201502301YA (en) | 2012-09-28 | 2013-09-27 | Azaquinazoline inhibitors of atypical protein kinase c |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US9914730B2 (en) |
| EP (1) | EP2900666B1 (en) |
| JP (1) | JP6535430B2 (en) |
| KR (1) | KR102215272B1 (en) |
| CN (1) | CN105102456B (en) |
| AU (1) | AU2013323360B2 (en) |
| BR (1) | BR112015007061B1 (en) |
| CA (1) | CA2886495C (en) |
| CL (1) | CL2015000781A1 (en) |
| EA (1) | EA030253B1 (en) |
| HK (2) | HK1211928A1 (en) |
| IL (1) | IL237918B (en) |
| MX (1) | MX2015004016A (en) |
| NZ (1) | NZ706857A (en) |
| PH (1) | PH12015500689A1 (en) |
| SG (1) | SG11201502301YA (en) |
| TW (1) | TWI663165B (en) |
| WO (1) | WO2014052699A1 (en) |
| ZA (1) | ZA201502783B (en) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102215272B1 (en) * | 2012-09-28 | 2021-02-15 | 이그니타, 인코포레이티드 | Azaquinazoline inhibitors of atypical protein kinase c |
| CA2895129C (en) | 2012-12-20 | 2022-07-05 | Sanford-Burnham Medical Research Institute | Quinazoline neurotensin receptor 1 agonists and uses thereof |
| AP2015008601A0 (en) | 2013-03-14 | 2015-07-31 | Boehringer Ingelheim Int | Substituted 2-aza-bicyclo[2.2.1] heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin C |
| EP3035936B1 (en) | 2013-08-23 | 2019-03-13 | NeuPharma, Inc. | Certain chemical entities, compositions, and methods |
| WO2015143376A1 (en) * | 2014-03-21 | 2015-09-24 | Nivalis Therapeutics, Inc. | Novel compounds for the treatment of cystic fibrosis |
| TWI675836B (en) * | 2014-03-25 | 2019-11-01 | 美商伊格尼塔公司 | Azaquinazoline inhibitors of atypical protein kinase c |
| CA2952732C (en) | 2014-06-25 | 2024-01-02 | Sanford-Burnham Medical Research Institute | Small molecule agonists of neurotensin receptor 1 |
| TW201613919A (en) | 2014-07-02 | 2016-04-16 | Pharmacyclics Llc | Inhibitors of Bruton's tyrosine kinase |
| WO2016037106A1 (en) * | 2014-09-05 | 2016-03-10 | Allosteros Therapeutics, Inc | CaMKII INHIBITORS AND USES THEREOF |
| CN108047240B (en) | 2014-09-12 | 2020-08-04 | 勃林格殷格翰国际有限公司 | Spirocyclic compound inhibitors of cathepsin C |
| US9834550B2 (en) | 2014-10-29 | 2017-12-05 | Dong-A St Co., Ltd. | Pyridopyrimidinone compounds for modulating the catalytic activity of histone lysine demethylases (KDMs) |
| CN105288512A (en) * | 2015-12-08 | 2016-02-03 | 李野林 | Traditional Chinese medicine composition for treating obesity |
| MX2018015483A (en) | 2016-06-13 | 2019-03-18 | Glaxosmithkline Ip Dev Ltd | Substituted pyridines as inhibitors of dnmt1. |
| CN109843858B (en) * | 2016-08-15 | 2023-05-05 | 润新生物公司 | Certain chemical entities, compositions and methods |
| CA3034239A1 (en) * | 2016-08-16 | 2018-02-22 | Merck Patent Gmbh | 2-oxo-imidazopyridines as reversible btk inhibitors and uses thereof |
| CN109715163B (en) | 2016-09-19 | 2022-11-22 | 诺华股份有限公司 | Therapeutic combination comprising a RAF inhibitor and an ERK inhibitor |
| JOP20190257A1 (en) * | 2017-04-28 | 2019-10-28 | Novartis Ag | 6-6 fused bicyclic heteroaryl compounds and their use as lats inhibitors |
| CA3057969A1 (en) | 2017-05-02 | 2018-11-08 | Novartis Ag | Combination therapy |
| CN110582491B (en) | 2017-06-30 | 2023-09-29 | 北京泰德制药股份有限公司 | Rho-related protein kinase inhibitor, pharmaceutical composition containing Rho-related protein kinase inhibitor, and preparation method and application of Rho-related protein kinase inhibitor |
| KR102563325B1 (en) | 2017-06-30 | 2023-08-03 | 베이징 타이드 파마슈티컬 코퍼레이션 리미티드 | ROH-related protein kinase inhibitors, pharmaceutical compositions containing RS-related protein kinase inhibitors, manufacturing methods and uses of pharmaceutical compositions |
| CN110582489B (en) | 2017-06-30 | 2023-10-27 | 北京泰德制药股份有限公司 | Rho-related protein kinase inhibitor, pharmaceutical composition containing Rho-related protein kinase inhibitor, and preparation method and application of Rho-related protein kinase inhibitor |
| JP7093462B2 (en) * | 2018-07-25 | 2022-06-29 | ファエス・ファルマ・ソシエダッド・アノニマ | Pyrimidine as a histamine H4 receptor inhibitor |
| CN112638899B (en) * | 2018-08-01 | 2023-09-05 | 上海轶诺药业有限公司 | Preparation and application of aromatic compound with immunoregulation function |
| CN111100063B (en) * | 2018-10-25 | 2022-05-17 | 南京药石科技股份有限公司 | Preparation method for synthesizing 2-fluoromethyl substituted pyrrolidine, piperidine and piperazine derivatives |
| EP3947380A4 (en) * | 2019-03-28 | 2023-01-11 | Cancer Research Technology Ltd | Inhibitors of atypical protein kinase c and their use in treating hedgehog pathway-dependent cancers |
| CN114349711B (en) * | 2022-02-28 | 2023-08-15 | 四川依维欣医药科技有限公司 | Synthesis method of (R) -1-Boc-3-hydroxymethyl piperazine |
| WO2024129737A1 (en) * | 2022-12-13 | 2024-06-20 | Varian Biopharmaceuticals, Inc. | Solid forms of {5-cyclopropyl-2-[2-(3,6-difluoro- pyridin-2-ylamino)-pyridin-4-yl]-pyrido[3,4-d]pyrimidin-4-yl}-((s)-3,3-dimethyl-piperidin-4-yl)-amine |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS4936700A (en) | 1972-08-16 | 1974-04-05 | ||
| US6184226B1 (en) * | 1998-08-28 | 2001-02-06 | Scios Inc. | Quinazoline derivatives as inhibitors of P-38 α |
| JP2002080423A (en) * | 2000-09-06 | 2002-03-19 | Daikin Ind Ltd | Method for synthesizing ethyl trifluoroacetate |
| JP2004509115A (en) | 2000-09-15 | 2004-03-25 | バーテックス ファーマシューティカルズ インコーポレイテッド | Pyrazole compounds useful as protein kinase inhibitors |
| FR2846657B1 (en) | 2002-11-05 | 2004-12-24 | Servier Lab | NOVEL PYRIDOPYRIMIDINONE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
| WO2004092196A2 (en) * | 2003-04-09 | 2004-10-28 | Exelixis, Inc. | Tie-2 modulators and methods of use |
| US20050038047A1 (en) | 2003-08-14 | 2005-02-17 | Edwards Paul John | Azaquinazoline derivatives |
| US7582631B2 (en) * | 2004-01-14 | 2009-09-01 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
| AU2006217744A1 (en) * | 2005-02-25 | 2006-08-31 | Kudos Pharmaceuticals Limited | 2,4-diamino-pyridopyrimidine derivatives and their use as MTOR inhibitors |
| RU2445312C2 (en) * | 2006-08-23 | 2012-03-20 | Кудос Фармасьютиклз Лимитед | 2-METHYLMORPHOLINE PYRIDO-, PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS |
| CA2662768A1 (en) * | 2006-09-08 | 2008-03-20 | Pfizer Products Inc. | Synthesis of 2-(pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones |
| WO2011029054A1 (en) * | 2009-09-04 | 2011-03-10 | The Regents Of The University Of Michigan | Compositions and methods for treatment of leukemia |
| KR102215272B1 (en) * | 2012-09-28 | 2021-02-15 | 이그니타, 인코포레이티드 | Azaquinazoline inhibitors of atypical protein kinase c |
| WO2014164543A1 (en) * | 2013-03-13 | 2014-10-09 | The Regents Of The University Of Michigan | Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof |
| US10246464B2 (en) * | 2014-09-09 | 2019-04-02 | The Regents Of The University Of Michigan | Thienopyrimidine and thienopyridine compounds and methods of use thereof |
| WO2017112768A1 (en) * | 2015-12-22 | 2017-06-29 | Vitae Pharmaceuticals, Inc. | Inhibitors of the menin-mll interaction |
-
2013
- 2013-09-27 KR KR1020157010868A patent/KR102215272B1/en active IP Right Grant
- 2013-09-27 JP JP2015534689A patent/JP6535430B2/en active Active
- 2013-09-27 US US14/038,915 patent/US9914730B2/en active Active
- 2013-09-27 CA CA2886495A patent/CA2886495C/en active Active
- 2013-09-27 MX MX2015004016A patent/MX2015004016A/en active IP Right Grant
- 2013-09-27 TW TW102134928A patent/TWI663165B/en active
- 2013-09-27 BR BR112015007061-2A patent/BR112015007061B1/en active IP Right Grant
- 2013-09-27 NZ NZ706857A patent/NZ706857A/en unknown
- 2013-09-27 CN CN201380062263.9A patent/CN105102456B/en active Active
- 2013-09-27 SG SG11201502301YA patent/SG11201502301YA/en unknown
- 2013-09-27 AU AU2013323360A patent/AU2013323360B2/en active Active
- 2013-09-27 WO PCT/US2013/062085 patent/WO2014052699A1/en active Application Filing
- 2013-09-27 EP EP13774578.2A patent/EP2900666B1/en active Active
- 2013-09-27 EA EA201590661A patent/EA030253B1/en not_active IP Right Cessation
-
2015
- 2015-03-24 IL IL237918A patent/IL237918B/en active IP Right Grant
- 2015-03-26 PH PH12015500689A patent/PH12015500689A1/en unknown
- 2015-03-27 CL CL2015000781A patent/CL2015000781A1/en unknown
- 2015-04-23 ZA ZA2015/02783A patent/ZA201502783B/en unknown
- 2015-12-18 US US14/975,605 patent/US9896446B2/en active Active
- 2015-12-28 HK HK15112771.3A patent/HK1211928A1/en unknown
-
2016
- 2016-01-08 HK HK16100191.9A patent/HK1212336A1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1212336A1 (en) | Azaquinazoline inhibitors of atypical protein kinase | |
| HK1215577A1 (en) | Protein kinase inhibitors | |
| IL232559A0 (en) | Thienopyrimidine inhibitors of atypical protein kinase c | |
| HK1200451A1 (en) | Protein kinase inhibitors | |
| HK1198360A1 (en) | Heterocyclic protein kinase inhibitors | |
| EP2694517A4 (en) | Protein kinase inhibitors | |
| EP2833889A4 (en) | Protein kinase c inhibitors and uses thereof | |
| ZA201306855B (en) | Protein kinase inhibitors | |
| HK1205507A1 (en) | Protein kinase inhibitors | |
| HK1209726A1 (en) | Protein kinase inhibitors | |
| HK1208460A1 (en) | Protein kinase inhibitors | |
| EP2838531A4 (en) | Indolin-2-one derivatives as protein kinase inhibitors | |
| HK1222339A1 (en) | Inhibitors of metallo-ss-lactamase-enzymes -- | |
| HK1210036A1 (en) | Aminoisoquinoline derivatives as protein kinase inhibitors | |
| IL240763B (en) | Halogenopyrazoles as inhibitors of therombin | |
| HK1201066A1 (en) | Pyranopyridone inhibitors of tankyrase | |
| EP2988738A4 (en) | Therapeutic indications of kinase inhibitors | |
| PL2888228T3 (en) | Inhibitors of cd40-traf6 interaction | |
| EP3560952C0 (en) | Variant of bpifb4 protein | |
| GB201323021D0 (en) | Use of kinase inhibitors | |
| GB201321227D0 (en) | Use of kinase inhibitors | |
| GB201216008D0 (en) | Novel use of GSK-3 inhibitors |